News & Updates

New drug applications approved by US FDA as of 1-15 March 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Patients with Sjögren disease (SD) are at heightened risk of mortality from infections, malignancies, and cardiovascular disease (CVD), reveals a study.

Among middle-aged women, low creatinine-cystatin C ratio is predictive of reduced fat-free muscle volumes and poorer gait speeds after more than 6 years, as shown in a study.

Individuals with rheumatoid arthritis (RA) are at an increased risk of developing anxiety or both depression and anxiety, according to a study.

Chronic pain is accompanied by depression and anxiety in 40 percent of adults, according to the results of a meta-analysis.

Treatment with abaloparatide appears to reduce the incidence of fractures as well as improve bone mineral density (BMD) in the subgroup of postmenopausal women at highest risk of fracture, according to a post hoc analysis of the ACTIVE* study.

Use of the Apollo wearable for 1 month leads to improvements in fatigue and Raynaud phenomenon (RP) symptoms in patients with systemic sclerosis (SSc), according to a pilot study.

New drug applications approved by US FDA as of 16-28 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The attainment of remission in EGPA is durable whether treated with benralizumab for 2 years or switched to benralizumab after 52 weeks of mepolizumab treatment, with additional merits observed among those who switched, as indicated in the OLE of MANDARA